Annual profit/loss of Sobi 2009-2022
Swedish biopharmaceutical company Sobi made annual losses in some years before 2015. However, the company made profits which increased significantly since then, with a peak in 2019 of around 3.3 billion Swedish kronor. In 2022, profits amounted to some 2.6 billion kroner. The company's full name is Swedish Orphan Biovitrum AB. Sobi is specialized on the treatment of rare diseases. This statistic illustrates the annual profit/loss of Sobi from 2009 to 2022.
